Zilovertamab is under clinical development by Oncternal Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Zilovertamab’s likelihood of approval (LoA) and phase transition for Triple-Negative Breast Cancer (TNBC) took place on 06 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Zilovertamab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Zilovertamab overview

Zilovertamab (UC-961) is under development for the treatment of relapsed or refractory chronic lymphocytic leukemia, marginal zone b-cell lymphoma, metastatic castration resistant prostate cancer, relapsed or refractory diffuse large B-cell lymphoma, metastatic or locally advanced unresectable triple negative breast cancer, HER2 negative breast cancer and mantle cell leukemia. The therapeutic candidate is administered intravenously and it acts by targeting ROR1. It was under development for ovarian cancer.

Oncternal Therapeutics overview

Oncternal Therapeutics (Oncternal), formerly GTx, is a biopharmaceutical company that discovers, develops, and commercializes novel targeted hormonal therapies. It develops small molecules that target hormone pathways for the treatment of various cancers, including breast and prostate cancer and other serious medical conditions. The company’s pipeline program includes cirmtuzumab, a humanized monoclonal antibody for the treatment of chronic lymphocytic leukemia, metastatic breast cancer and and mantle cell lymphoma; TK216 for treatment of Ewing sarcoma, prostate cancer and acute myeloid lukemia and a ROR1-targeted CAR-T therapy candidate for treatment hematologic and solid tumors. It conducts preclinical development activities in the US and Europe. Oncternal is headquartered in San Diego, California, the US.

Quick View Zilovertamab LOA Data

Report Segments
  • Innovator
Drug Name
  • Zilovertamab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.